A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

NCT06568237

Status	RECRUITING
Phase	Phase 2
Sponsor	Teva Branded Pharmaceutical Products R&D LLC
Enrollment	350 participants

Key Eligibility Criteria

Inclusion (6)

- is considered to be "clinically possible" or "clinically probable" MSA as determined by the Gilman criteria
- is medically and psychiatrically stable, as indicated by medical and psychiatric history, as well as physical and neurological examination
- Females of child bearing potential (CBP) may be included only if they have a negative pregnancy test at the screening and baseline visits
- Females of CBP whose male partners are potentially fertile (ie, no vasectomy) must use highly effective birth control methods
- Males who are potentially fertile/reproductively competent (not surgically \[eg, vasectomy\] or congenitally sterile) and their female partners who are of CBP must use, together with their female partners, highly effective birth control methods

... and 1 more (see full listing online)

Exclusion (8)

- has 2 or more relatives with history of MSA, suggestive of an alternative diagnosis other than MSA
- has participated in another clinical study involving administration of an IMP within 3 months or 5 half-lives (whichever is longer) of this IMP prior to screening
- has a history of, or acknowledges, alcohol or other substance abuse in the 12 months before screening
- is a female participant who is pregnant or breastfeeding, or plans to become pregnant during the study
- has a known hypersensitivity to any components of the IMP

... and 3 more (see full listing online)

Locations (54 total)

Teva Investigational Site 15554, La Jolla, California, United States
Teva Investigational Site 15545, Los Angeles, California, United States
Teva Investigational Site 15547, Washington D.C., District of Columbia, United States
... and 51 more locations